Overview

Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers

Status:
Completed
Trial end date:
2018-01-31
Target enrollment:
0
Participant gender:
All
Summary
Aprepitant is an oral neurokinin-1(NK-1) antagonist which is widely used for the prevention of chemotherapy-induced nausea and vomiting(CINV), it is metabolized by CYP34A, however, up to now it was still unknown the CINV control rate of aprepitant in Chinese non-small cell lung cancer(NSCLC) patients, we hypothesis that CYP3A4 and NK-1 polymorphism would influence aprepitant plasma concentration, which may lead to the individual difference of CINV control rate.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Hunan Province Tumor Hospital
Treatments:
Aprepitant
Fosaprepitant
Criteria
Inclusion Criteria:

- patients pathologic diagnosed of advanced non-small cell lung cancer

- according to NCCN non-small cell lung cancer guide line(2014 V2), patients are
suitable for platinum based chemotherapy.

Exclusion Criteria:

- patients could not receive platinum based chemotherapy judged by clinical doctors

- pregnancy or breast-feeding women

- any serious disease which could not be controled

- urine proteinā‰„++, or 24h urine protein>1g

- less than 18 years old or more than 75 years old